<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(2)</volume><submitter>Barmade MA</submitter><funding>University Grants Commission</funding><funding>Department of Biotechnology, Ministry of Science and Technology, India</funding><pubmed_abstract>The emergence of drug resistance against the frontline antimalarials is a major challenge in the treatment of malaria. In view of emerging reports on drug-resistant strains of &lt;i>Plasmodium&lt;/i> against artemisinin combination therapy, a dire need is felt for the discovery of novel compounds acting against novel targets in the parasite. In this study, we identified a novel series of quinolinepiperazinyl-aryltetrazoles (QPTs) targeting the blood stage of &lt;i>Plasmodium&lt;/i>. &lt;i>In vitro&lt;/i> anti-plasmodial activity screening revealed that most of the compounds showed IC&lt;sub>50&lt;/sub> &lt; 10 μM against chloroquine-resistant &lt;i>Pf&lt;/i>INDO strain, with the most promising lead compounds 66 and 75 showing IC&lt;sub>50&lt;/sub> values of 2.25 and 1.79 μM, respectively. Further, compounds 64-66, 68, 75-77 and</pubmed_abstract><journal>RSC medicinal chemistry</journal><pagination>572-594</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10880932</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Novel quinolinepiperazinyl-aryltetrazoles targeting the blood stage of &lt;i>Plasmodium falciparum&lt;/i>.</pubmed_title><pmcid>PMC10880932</pmcid><pubmed_authors>Yadav MR</pubmed_authors><pubmed_authors>Rana B</pubmed_authors><pubmed_authors>Sahal D</pubmed_authors><pubmed_authors>Barmade MA</pubmed_authors><pubmed_authors>Agrawal P</pubmed_authors><pubmed_authors>Rajput SR</pubmed_authors><pubmed_authors>Murumkar PR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Novel quinolinepiperazinyl-aryltetrazoles targeting the blood stage of &lt;i>Plasmodium falciparum&lt;/i>.</name><description>The emergence of drug resistance against the frontline antimalarials is a major challenge in the treatment of malaria. In view of emerging reports on drug-resistant strains of &lt;i>Plasmodium&lt;/i> against artemisinin combination therapy, a dire need is felt for the discovery of novel compounds acting against novel targets in the parasite. In this study, we identified a novel series of quinolinepiperazinyl-aryltetrazoles (QPTs) targeting the blood stage of &lt;i>Plasmodium&lt;/i>. &lt;i>In vitro&lt;/i> anti-plasmodial activity screening revealed that most of the compounds showed IC&lt;sub>50&lt;/sub> &lt; 10 μM against chloroquine-resistant &lt;i>Pf&lt;/i>INDO strain, with the most promising lead compounds 66 and 75 showing IC&lt;sub>50&lt;/sub> values of 2.25 and 1.79 μM, respectively. Further, compounds 64-66, 68, 75-77 and</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-06-03T00:24:31.145Z</modification><creation>2025-04-04T23:31:40.049Z</creation></dates><accession>S-EPMC10880932</accession><cross_references><pubmed>38389888</pubmed><doi>10.1039/d3md00417a</doi></cross_references></HashMap>